Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: Efficacy and cost analysis study Journal Article


Authors: Afifi, S.; Adel, N. G.; Devlin, S.; Duck, E.; Vanak, J.; Landau, H.; Chung, D. J.; Lendvai, N.; Lesokhin, A.; Korde, N.; Reich, L.; Landgren, O.; Giralt, S.; Hassoun, H.
Article Title: Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: Efficacy and cost analysis study
Abstract: Cyclophosphamide plus G-CSF (C+G-CSF) is one of the most widely used stem cell (SC) mobilization regimens for patients with multiple myeloma (MM). Plerixafor plus G-CSF (P+G-CSF) has demonstrated superior SC mobilization efficacy when compared with G-CSF alone and has been shown to rescue patients who fail mobilization with G-CSF or C+G-CSF. Despite the proven efficacy of P+G-CSF in upfront SC mobilization, its use has been limited, mostly due to concerns of high price of the drug. However, a comprehensive comparison of the efficacy and cost effectiveness of SC mobilization using C+G-CSF versus P+G-CSF is not available. In this study, we compared 111 patients receiving C+G-CSF to 112 patients receiving P+G-CSF. The use of P+G-CSF was associated with a higher success rate of SC collection defined as >= 5x10(6) CD34+ cells/kg (94 versus 83%, P=0.013) and less toxicities. Thirteen patients in the C+G-CSF arm were hospitalized owing to complications while none in the P+G-CSF group. C+G-CSF was associated with higher financial burden as assessed using institutional-specific costs and charges (P<0.001) as well as using Medicare reimbursement rates (P=0.27). Higher rate of hospitalization, increased need for salvage mobilization, and increased G-CSF use account for these differences.
Keywords: chemotherapy; transplantation; growth-factor; non-hodgkins-lymphoma; colony-stimulating factor; amd3100; rescue; autologous; hematopoietic stem; lenalidomide therapy; adequate pbsc collection
Journal Title: Bone Marrow Transplantation
Volume: 51
Issue: 4
ISSN: 0268-3369
Publisher: Nature Publishing Group  
Date Published: 2016-04-01
Start Page: 546
End Page: 552
Language: English
ACCESSION: WOS:000373360400013
DOI: 10.1038/bmt.2015.322
PROVIDER: wos
PUBMED: 26726942
PMCID: PMC7337097
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Sergio Andres Giralt
    1053 Giralt
  2. Hani Hassoun
    329 Hassoun
  3. Heather Jolie Landau
    419 Landau
  4. Nikoletta Lendvai
    106 Lendvai
  5. Jill M Vanak
    14 Vanak
  6. Lilian M Reich
    99 Reich
  7. Alexander Meyer Lesokhin
    363 Lesokhin
  8. David Chung
    240 Chung
  9. Nelly G Adel
    44 Adel
  10. Elaine Duck
    19 Duck
  11. Sean McCarthy Devlin
    601 Devlin
  12. Salma H Afifi
    9 Afifi
  13. Carl Ola Landgren
    336 Landgren
  14. Neha Sanat Korde
    226 Korde